Genetic basis of autoimmunity

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2234-2241

  Marson, Alexander ^a   Housley, William J ^b   Hafler, David A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD6 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; GENE; GENE EXPRESSION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; IMMUNE DYSREGULATION; META ANALYSIS (TOPIC); MONOGENIC DISORDER; NONHUMAN; PRIORITY JOURNAL; TNFRSF1A GENE; ANIMAL; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENOTYPE ENVIRONMENT INTERACTION; IMMUNOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DATABASES, GENETIC; GENE EXPRESSION REGULATION; GENE-ENVIRONMENT INTERACTION; GENOME-WIDE ASSOCIATION STUDY; HUMANS;

EID: 84930387310     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78086     Document Type: Article

References (116)

1. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33(3-4): 197-207.
2. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell. 1996;85(3): 311-318.
3. Sadovnick AD, et al. A population-based study of multiple sclerosis in twins: Update. Ann Neurol. 1993;33(3): 281-285.
4. Ebers GC, et al. A population-based study of multiple sclerosis in twins. N Engl J Med. 1986;315(26): 1638-1642.
5. Sadovnick AD, Baird PA, Ward RH. Multiple sclerosis: Updated risks for relatives. Am J Med Genet. 1988;29(3): 533-541.
6. Sadovnick AD, Baird PA. The familial nature of multiple sclerosis: Age-corrected empiric recurrence risks for children and siblings of patients. Neurology. 1988;38(6): 990-991.
7. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature. 1995;377(6545): 150-151.
8. Cheng MH, Anderson MS. Monogenic autoimmunity. Annu Rev Immunol. 2012;30: 393-427.
9. Bennett CL, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27(1): 20-21.
10. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4): 330-336.
11. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609): 1057-1061.
12. Wildin RS, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27(1): 18-20.
13. Anderson MS, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298(5597): 1395-1401.
14. Nagamine K, et al. Positional cloning of the APECED gene. Nat Genet. 1997;17(4): 393-398.
15. Klamp T, Sahin U, Kyewski B, Schwendemann J, Dhaene K, Tureci O. Expression profiling of autoimmune regulator AIRE mRNA in a comprehensive set of human normal and neoplastic tissues. Immunol Lett. 2006;106(2): 172-179.
16. Heino M, et al. RNA and protein expression of the murine autoimmune regulator gene (Aire) in normal, RelB-deficient and in NOD mouse. Eur J Immunol. 2000;30(7): 1884-1893.
17. Heino M, et al. Autoimmune regulator is expressed in the cells regulating immune tolerance in thymus medulla. Biochem Biophys Res Commun. 1999;257(3): 821-825.
18. Aaltonen J, Bjorses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: Autoimmune polyglandular disease type I assigned to chromosome 21. Nat Genet. 1994;8(1): 83-87.
19. Schubert D, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12): 1410-1416.
20. Zeissig S, et al. Early-onset Crohn's disease autoimmunity associated with a variant in CTLA-4 [published online ahead of print November 3, 2014]. Gut. doi: 10.1136/gutjnl-2014-308541.
21. Kuehn HS, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204): 1623-1627.
22. Chu X, et al. A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet. 2011;43(9): 897-901.
23. Onengut-Gumuscu S, et al. Fine mapping of type 1 diabetes susceptibility loci evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015;47(4): 381-386.
24. Maier LM, Anderson DE, De Jager PL, Wicker LS, Hafler DA. Allelic variant in CTLA4 alters T cell phosphorylation patterns. Proc Natl Acad Sci U S A. 2007;104(47): 18607-18612.
25. Brewerton DA, Caffrey M, Nicholls A, Walters D, James DC. Acute anterior uveitis and HL-A 27. Lancet. 1973;302(7836): 994-996.
26. Brewerton DA, Caffrey M, Nicholls A, Walters D, Oates JK, James DC. Reiter's disease and HL-A 27. Lancet. 1973;302(7836): 996-998.
27. Woodrow JC. HL-A 27 and Reiter's syndrome. Lancet. 1973;2(7830): 671-672.
28. Hampe J, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001;357(9272): 1925-1928.
29. Hugot JP, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837): 599-603.
30. Ogura Y, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411(6837): 603-606.
31. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science. 2008;322(5903): 881-888.
32. Hindorff LA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009;106(23): 9362-9367.
33. Welter D, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42(Database issue): D1001-D1006.
34. Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009;10(1): 43-55.
35. Cotsapas C, et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 2011;7(8): E1002254.
36. Cotsapas C, Hafler DA. Immune-mediated disease genetics: The shared basis of pathogenesis. Trends Immunol. 2013;34(1): 22-26.
37. Farh KK, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518(7539): 337-343.
38. Hu X, Kim H, Stahl E, Plenge R, Daly M, Raychaudhuri S. Integrating autoimmune risk loci with gene-expression data identifies specific pathogenic immune cell subsets. Am J Hum Genet. 2011;89(4): 496-506.
39. Heng TS, Painter MW, Immunological Genome Project C. The Immunological Genome Project: Networks of gene expression in immune cells. Nat Immunol. 2008;9(10): 1091-1094.
40. Zhang W, et al. Effector CD4+ T cell expression signatures and immune-mediated disease associated genes. PLoS One. 2012;7(6): E38510.
41. Rossin EJ, et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet. 2011;7(1): E1001273.
42. Segre AV, et al. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet. 2010;6(8): E1001058.
43. Franke L, van Bakel H, Fokkens L, de Jong ED, Egmont-Petersen M, Wijmenga C. Reconstruction of a functional human gene network, with an application for prioritizing positional candidate genes. Am J Hum Genet. 2006;78(6): 1011-1025.
44. International Multiple Sclerosis Genetics Consortium. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am J Hum Genet. 2013;92(6): 854-865.
45. Stanford SM, Bottini N. PTPN22: The archetypal non-HLA autoimmunity gene. Nat Rev Rheumatol. 2014;10(10): 602-611.
46. Wang Y, et al. The autoimmunity-Associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity. 2013;39(1): 111-122.
47. International Consortium for Systemic Lupus Erythematosus Genetics, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40(2): 204-210.
48. Begovich AB, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004;75(2): 330-337.
49. Bottini N, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004;36(4): 337-338.
50. Kyogoku C, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004;75(3): 504-507.
51. Velaga MR, et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab. 2004;89(11): 5862-5865.
52. Baranathan V, et al. The association of the PTPN22 620W polymorphism with Behcet's disease. Ann Rheum Dis. 2007;66(11): 1531-1533.
53. Begovich AB, et al. The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis. Am J Hum Genet. 2005;76(1): 184-187.
54. Criswell LA, et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: The PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet. 2005;76(4): 561-571.
55. De Jager PL, et al. Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis. Eur J Hum Genet. 2006;14(3): 317-321.
56. Rivas MA, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011;43(11): 1066-1073.
57. Vang T, et al. Autoimmune-Associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet. 2005;37(12): 1317-1319.
58. Zhang J, et al. The autoimmune disease-Associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet. 2011;43(9): 902-907.
59. Rawlings DJ, Dai X, Buckner JH. The role of PTPN22 risk variant in the development of autoimmunity: Finding common ground between mouse and human. J Immunol. 2015;194(7): 2977-2984.
60. Menard L, et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest. 2011;121(9): 3635-3644.
61. Arechiga AF, et al. Cutting edge: The PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol. 2009;182(6): 3343-3347.
62. Hassan NJ, et al. CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76. Mol Cell Biol. 2006;26(17): 6727-6738.
63. De Jager PL, et al. Meta-Analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41(7): 776-782.
64. Kofler DM, Severson CA, Mousissian N, De Jager PL, Hafler DA. The CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4+ T cell proliferation. J Immunol. 2011;187(6): 3286-3291.
65. International Multiple Sclerosis Genetics Consortium Wellcome Trust Case Control Consortium 2, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359): 214-219.
66. International Multiple Sclerosis Genetics Consortium, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45(11): 1353-1360.
67. Ottoboni L, et al. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013;81(22): 1891-1899.
68. Gregory AP, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 2012;488(7412): 508-511.
69. Comabella M, et al. TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. Neurology. 2013;80(22): 2010-2016.
70. Housley WJ, et al. Genetic variants associated with autoimmunity drive NF?B signaling and responses to inflammatory stimuli. Sci Transl Med. In Press.
71. Hnisz D, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4): 934-947.
72. Hartmann FJ, et al. Multiple sclerosis-Associated IL2RA polymorphism controls GM-CSF production in human TH cells. Nat Commun. 2014;5: 5056.
73. Cerosaletti K, et al. Multiple autoimmune-Associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. PLoS One. 2013;8(12): E83811.
74. Dendrou CA, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet. 2009;41(9): 1011-1015.
75. Ye CJ, et al. Intersection of population variation and autoimmunity genetics in human T cell activation. Science. 2014;345(6202): 1254665.
76. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther. 2011;13(1): 101.
77. Trynka G, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet. 2011;43(12): 1193-1201.
78. Cooper JD, et al. Seven newly identified loci for autoimmune thyroid disease. Hum Mol Genet. 2012;21(23): 5202-5208.
79. Liu JZ, et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2012;44(10): 1137-1141.
80. Cortes A, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45(7): 730-738.
81. Ellinghaus D, et al. High-density genotyping study identifies four new susceptibility loci for atopic dermatitis. Nat Genet. 2013;45(7): 808-812.
82. Liu JZ, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet. 2013;45(6): 670-675.
83. Hinks A, et al. Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet. 2013;45(6): 664-669.
84. Tsoi LC, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12): 1341-1348.
85. Chen GB, et al. Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data. Hum Mol Genet. 2014;23(17): 4710-4720.
86. Wellcome Trust Case Control Consortium, et al. Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet. 2012;44(12): 1294-1301.
87. 1000 Genomes Project Consortium, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422): 56-65.
88. Rivera CM, Ren B. Mapping human epigenomes. Cell. 2013;155(1): 39-55.
89. Shlyueva D, Stampfel G, Stark A. Transcriptional enhancers: From properties to genome-wide predictions. Nat Rev Genet. 2014;15(4): 272-286.
90. Villar D, Flicek P, Odom DT. Evolution of transcription factor binding in metazoans - mechanisms and functional implications. Nat Rev Genet. 2014;15(4): 221-233.
91. Ernst J, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature. 2011;473(7345): 43-49.
92. Heintzman ND, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 2009;459(7243): 108-112.
93. Marson A, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature. 2007;445(7130): 931-935.
94. Samstein RM, et al. Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. Cell. 2012;151(1): 153-166.
95. Ciofani M, et al. A validated regulatory network for Th17 cell specification. Cell. 2012;151(2): 289-303.
96. Maurano MT, et al. Systematic localization of common disease-Associated variation in regulatory DNA. Science. 2012;337(6099): 1190-1195.
97. Parker SC, et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc Natl Acad Sci U S A. 2013;110(44): 17921-17926.
98. Trynka G, et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet. 2013;45(2): 124-130.
99. Hawkins RD, et al. Global chromatin state analysis reveals lineage-specific enhancers during the initiation of human T helper 1 and T helper 2 cell polarization. Immunity. 2013;38(6): 1271-1284.
100. Gilad Y, Rifkin SA, Pritchard JK. Revealing the architecture of gene regulation: The promise of eQTL studies. Trends Genet. 2008;24(8): 408-415.
101. Stranger BE, et al. Population genomics of human gene expression. Nat Genet. 2007;39(10): 1217-1224.
102. Orru V, et al. Genetic variants regulating immune cell levels in health and disease. Cell. 2013;155(1): 242-256.
103. Wright FA, et al. Heritability and genomics of gene expression in peripheral blood. Nat Genet. 2014;46(5): 430-437.
104. Gat-Viks I, et al. Deciphering molecular circuits from genetic variation underlying transcriptional responsiveness to stimuli. Nat Biotechnol. 2013;31(4): 342-349.
105. Fairfax BP, et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science. 2014;343(6175): 1246949.
106. Hu X, et al. Regulation of gene expression in autoimmune disease loci and the genetic basis of proliferation in CD4+ effector memory T cells. PLoS Genet. 2014;10(6): E1004404.
107. Lee MN, et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science. 2014;343(6175): 1246980.
108. Raj T, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science. 2014;344(6183): 519-523.
109. Heinz S, et al. Effect of natural genetic variation on enhancer selection and function. Nature. 2013;503(7477): 487-492.
110. McVicker G, et al. Identification of genetic variants that affect histone modifications in human cells. Science. 2013;342(6159): 747-749.
111. Seumois G, et al. Epigenomic analysis of primary human T cells reveals enhancers associated with TH2 memory cell differentiation and asthma susceptibility. Nat Immunol. 2014;15(8): 777-788.
112. Manolio TA, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265): 747-753.
113. Okada Y, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488): 376-381.
114. Lee JC, et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell. 2013;155(1): 57-69.
115. Chakravarti A, Clark AG, Mootha VK. Distilling pathophysiology from complex disease genetics. Cell. 2013;155(1): 21-26.
116. Eyre S, Worthington J. Take your PICS: Moving from GWAS to immune function. Immunity. 2014;41(6): 883-885.